Saturday 17 October 2026 Export GYRE’s income statement to Excel — free account

Gyre Therapeutics, Inc.

In the quarter to June 2026, revenue fell 2.12%, EPS was flat and free cash flow fell 130.5%, each against the same quarter a year earlier.

6.08 0.32 −5.00%

Follow GYRE

Alert me

Market cap: $678.6M
P/E: 0.0×
Fwd P/E: −21.7×
Dividend yield: —
F-score: 4/9
Altman Z: 16.83
Beneish M: −2.02
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 0.95

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	5	4	—	—	—	—

Insider Ownership 76.50%

Capital & Financial Ratios $m

Market Cap 678.62

Revenue 116.42

Net Income (25.67)

Free Cash Flow (7.12)

Net Debt (74.80)

Current Ratio 4.26

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (21.70)

P/S ratio 5.26

P/B ratio 4.29

Past 5Y EPS Growth —

This Y EPS Growth (2,100.00%)

Next Y EPS Growth 41.25%

Next Y revenue growth (6.08%)

Next 5Y EPS Growth 21.64%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 20.16%

10-year low 10-year high

P/B against its own 10 years 73.42%

10-year low 10-year high

EV/Sales against its own 10 years 33.06%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	0.00	3.60
2022	0.00	21.45
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	34	27	52	75
Receivables	16	25	31	28
Inventory	4	6	10	11
Other	1	1	1	—
	57	65	102	122

	2023	2024	2025	Q'26
Payables	0	0	0	1
ST’ Debt	—	—	—	—
Other	0	5	0	—
	20	20	18	29

Compound Annual Growth %

	10y	5y	3y
Sales	51.64%	40.96%	4.46%
Cash Flow	0.00%	0.00%	(54.44%)
Earnings	0.00%	0.00%	29.74%
Book Value	16.30%	13.34%	25.36%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	23	29	—	—	—
’25	22	30	31	34	117
’24	27	25	25	28	106
’23	25	29	32	27	113
’22	1	—	—	101	102
’21	1	1	2	2	7
’20	16	2	1	2	21

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(17)	—	—	—
’25	0	(7)	14	(6)	1
’24	3	(5)	2	(3)	(4)
’23	10	5	8	3	26
’22	(12)	(12)	(7)	42	11
’21	(24)	(20)	(22)	(18)	(84)
’20	(5)	(15)	(13)	(22)	(55)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	3	(18)	—	—	—
’25	(1)	(8)	14	(6)	(1)
’24	3	(7)	1	(3)	(6)
’23	9	2	6	1	18
’22	(12)	(12)	(7)	37	6
’21	(24)	(20)	(22)	(18)	(85)
’20	(5)	(15)	(13)	(22)	(55)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.10)	(0.12)	—	—	—
’25	0.00	0.00	0.03	(0.02)	0.02
’24	0.03	0.01	0.01	0.00	0.05
’23	0.15	(1.05)	(0.60)	(1.49)	(1.41)
’22	(6.90)	24.59	(2.40)	(19.19)	(3.90)
’21	(11.84)	(9.60)	(11.99)	(9.60)	(43.03)
’20	(4.20)	(14.39)	(10.94)	(12.89)	(43.93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	119.25	46.65	93.00	67.80	51.45	13.50	5.25	2.85	8.26	6.11	Analyst estimates 2026–2028 Powerpack
	High	765.00	283.20	555.00	162.60	134.10	113.25	31.35	30.40	27.45	13.75
People
People	Employees	10	13	21	34	56	45	7	593	579	625
	Revenue/emp, $m	0.04	0.08	0.00	0.00	0.37	0.16	14.61	0.19	0.18	0.19
Income, $m
Income, $m	Revenue	0	1	0	—	21	7	102	113	106	117
	Gross margin, %	100.00	100.00	100.00	0.00	56.26	(0.57)	95.31	95.91	96.33	95.35
	EBT	(17)	(22)	(30)	(55)	(56)	(88)	9	(77)	23	14
	EBT margin, %	(4,246.87)	(2,117.98)	(500,916.67)	0.00	(268.48)	(1,198.32)	9.20	(67.84)	21.95	12.38
	Net income	(17)	(22)	(30)	(55)	(56)	(88)	4	(85)	18	10
	Depreciation	0	0	0	0	0	0	1	1	2	3
Per share, $
Per share, $	Revenue	7.67	4.46	0.01	0.00	16.38	3.59	1.61	1.72	1.24	1.30
	Earnings	(326.09)	(111.69)	(40.18)	(68.97)	(43.93)	(43.03)	(3.90)	(1.41)	0.14	0.06
	Cash flow	(355.23)	(87.30)	(38.17)	(54.47)	(43.03)	(40.98)	0.17	0.39	(0.04)	0.01
	Capex	40.31	(0.10)	(0.50)	(0.08)	(0.21)	(0.41)	(0.08)	(0.12)	(0.03)	(0.02)
	Free cash flow	(314.92)	(87.40)	(38.68)	(54.55)	(43.24)	(41.39)	0.09	0.27	(0.07)	(0.01)
	Book value	309.06	134.74	160.35	85.35	59.47	20.10	1.14	1.19	1.16	1.59
	Shares, m	0	0	1	1	1	2	64	66	85	89
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	—	0.00	0.00	0.00	0.00	86.43	141.20
	P/S	19.35	48.36	117.56	—	5.78	3.80	5.26	13.80	9.74	5.41
	P/B	0.48	1.60	0.74	—	1.59	0.68	7.79	112.28	10.46	10.59
	EV/Sales	(23.22)	16.39	(35.09)	—	2.24	(1.87)	5.07	13.56	9.53	4.66
	EV/FCF	0.57	(0.84)	0.91	—	(0.85)	0.16	95.36	85.58	(158.25)	(615.37)
Cash, $m
Cash, $m	Operating cash flow	(18)	(20)	(29)	(44)	(55)	(84)	11	26	(4)	1
	Capex	2	0	0	0	0	(1)	(5)	(8)	(3)	(2)
	Free cash flow	(16)	(20)	(29)	(44)	(55)	(85)	6	18	(6)	(1)
Balance, $m
Balance, $m	Working capital	16	30	119	67	72	37	37	37	45	84
	Total debt	19	5	—	0	1	2	0	—	—	—
	Net debt	(17)	(33)	(120)	(77)	(79)	(47)	(25)	(34)	(27)	(52)
	Shareholders’ equity	16	31	120	68	76	41	72	78	98	142
Returns, %
Returns, %	ROA	(31.49)	(65.75)	(36.56)	(49.38)	(58.16)	(116.85)	3.28	(92.34)	9.99	3.45
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	12.23	(93.45)	14.08	7.99
	ROE	(71.35)	(108.92)	(39.88)	(58.61)	(77.89)	(150.11)	4.06	(215.71)	21.51	4.18

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OABI OmniAb, Inc.	$687.7M	— (loss-making)	— (loss-making)	+244.24% (above 0%: growing)	n/m	+211.16% (above 0%: growing)	95.45%	(49.47%)	Compare
ANNX Annexon, Inc.	$682.5M	— (loss-making)	—	—	n/m	−26.41% (below 0%: shrinking)	0.00%	0.00%	Compare
MDXG MiMedx Group, Inc	$682.2M	111×	— (loss-making)	−34.73% (below 0%: shrinking)	n/m	−174.83% (below 0%: shrinking)	68.96%	(28.69%)	Compare
CADL Candel Therapeutics, Inc.	$681.8M	— (loss-making)	— (loss-making)	0.00%	n/m	−93.35% (below 0%: shrinking)	0.00%	0.00%	Compare
PHAR Pharming Group N.V. Sponsored ADR	$681.6M	62.4×	— (loss-making)	−3.22% (below 0%: shrinking)	−57.14% (below 0%: shrinking)	−183.87% (below 0%: shrinking)	83.92%	1.44%	Compare
GYRE Gyre Therapeutics, Inc.	$678.6M	— (loss-making)	— (loss-making)	−2.12% (below 0%: shrinking)	n/m	−130.45% (below 0%: shrinking)	92.41%	(49.35%)
AURA Aura Biosciences, Inc.	$657.5M	— (loss-making)	—	—	n/m	−56.26% (below 0%: shrinking)	0.00%	0.00%	Compare
DSGN Design Therapeutics, Inc.	$655.9M	— (loss-making)	— (loss-making)	—	n/m	−7.00% (below 0%: shrinking)	0.00%	0.00%	Compare
PRME Prime Medicine, Inc.	$654.8M	— (loss-making)	— (loss-making)	+3.50% (above 0%: growing)	n/m	+4.40% (above 0%: growing)	100.00%	(3,750.87%)	Compare
Median of peers	$681.7M	—	—	0.00%	—	−41.33%	34.48%	0.00%

All 614 Biotechnology stocks →

Gyre Therapeutics, Inc. (GYRE) key facts

Gyre Therapeutics, Inc. (GYRE) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, GYRE traded at $6.08, a market capitalization of $678.6 million.
Return on equity was 4.18% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 16.83 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.